indirubin-3'-monoxime has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 3 studies
indirubin-3'-monoxime: has antiangiogenic activity
indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Drug resistance in chronic myelogenous leukemia (CML) requires the development of new CML chemotherapeutic drugs." | 1.43 | Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. ( Gaboriaud-Kolar, N; Gerolymatos, P; Horne, DA; Jove, R; Mikros, E; Myrianthopoulos, V; Nam, S; Skaltsounis, AL; Vougogiannopoulou, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gaboriaud-Kolar, N | 1 |
| Myrianthopoulos, V | 1 |
| Vougogiannopoulou, K | 1 |
| Gerolymatos, P | 1 |
| Horne, DA | 1 |
| Jove, R | 1 |
| Mikros, E | 1 |
| Nam, S | 1 |
| Skaltsounis, AL | 1 |
| Wang, H | 1 |
| Wang, Z | 1 |
| Wei, C | 1 |
| Wang, J | 1 |
| Xu, Y | 1 |
| Bai, G | 1 |
| Yao, Q | 1 |
| Zhang, L | 1 |
| Chen, Y | 1 |
| Lee, MY | 1 |
| Liu, YW | 1 |
| Chen, MH | 1 |
| Wu, JY | 1 |
| Ho, HY | 1 |
| Wang, QF | 1 |
| Chuang, JJ | 1 |
1 review available for indirubin-3'-monoxime and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.
Topics: Antineoplastic Agents; Cell Survival; Chemistry, Pharmaceutical; Drugs, Chinese Herbal; Humans; Indo | 2021 |
2 other studies available for indirubin-3'-monoxime and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; CSK Tyrosine-Protein | 2016 |
Indirubin-3'-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells.
Topics: Apoptosis; Autophagy; Caspase 3; Cell Death; Cell Division; Cell Line, Tumor; Cell Survival; G2 Phas | 2013 |